Article
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
Cancer biology & therapy - 1 Sept 2014
de Martino Michela, Zhuang Dazhong, Klatte Tobias, Rieken Malte, Rouprêt Morgan, Xylinas Evanguelos, Clozel Thomas, Krzywinski Martin, Elemento Olivier, Shariat Shahrokh F
Abstract excerpt
Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC). We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of UBC and that these mutations impact ErbB2 function, signaling, UBC proliferation, gene expression, and predict response to lapatinib. We found ERBB2 mutations in 5...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.